

Technology Advisory Committee C Interests Register

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID3970]

Publication Date: 17 October 2023

Name	Role with NICE	Type of interest	Description of interest	Interests declared	Comments
Dr Mark Corbett	Committee Member	Non-financial professional	Dr Corbett works for the York external assessment group but has had no involvement with this appraisal.	28/06/2023	It was agreed that Dr Corbett's declaration would not prevent him from participating in discussions on this appraisal.
Dr Kate Ren	Committee Member	Indirect financial	Dr Ren has provided statistical methods consultancy services to one of the comparator companies (Jazz Pharmaceuticals) for a different treatment in a different disease area - cannabidiol for treating Lennox-Gastaut Syndrome.	03/07/2023	It was agreed that Dr Ren's declaration would not prevent her from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Indirect financial	Dr Nicholas has attended paid advisory boards for Roche in an unrelated disease area – multiple sclerosis	04/07/2023	It was agreed that Dr Nicholas' declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interests declared	Comments
Dr Wendy Osborne	Clinical Expert	Direct and indirect financial	<p>Dr Osborne has given educational talks, attended advisory boards and attended the EHA (June 2022) and ASH (Dec 2022) conferences with funding from Roche.</p> <p>Dr Osborne has also had speaking and advisory roles from 2013 to present for Roche, Pfizer, Gilead, BMS and AbbVie.</p>	<p>19/12/2022</p> <p>05/08/2023</p>	It was agreed that Dr Osborne's declaration would not prevent her from providing expert advice to the committee.
Dr William Townsend	Clinical Expert	Direct and indirect financial and non-financial	<p>Dr Townsend has received honoraria for giving talks, fees for participating in advisory boards, and fees to cover travel and registration at international conferences from Roche, Gilead and BMS.</p> <p>Dr Townsend will be the lead investigator for an investigator-initiated academic clinical trial assessing glofitamab in combination with polatuzumab in patients with relapse lymphoma. This is an academic trial currently in development</p>	06/12/2022	It was agreed that Dr Townsend's declarations would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interests declared	Comments
			<p>and due to open in 2023. It's design and concept are his own. He will receive no financial payment for this trial. The sponsor, UCL, his employer, will hold a contract with Roche to deliver this trial.</p> <p>Dr Townsend is also a considered expert in the area of bispecific antibody therapy and has given a number of non-paid talks at academic meetings about these drugs as they have been developed.</p>		